Skip to main content
Premium Trial:

Request an Annual Quote

Novartis and Compugen Launch RNA Interference Project

NEW YORK, Sept. 4-Novartis and Compugen are extending their research collaboration to include target validation and RNA interference research, the two companies said today.

 

The two companies intend to build a large-scale platform that can generate a library of transcript-inhibiting molecules. Compugen will own the platform and have rights to use it internally and as a commercial product. Novartis will use the system for its own research and will own the results of that work.

 

Novartis plans to use the RNAi platform to synthesize transcript-inhibiting molecules and use them to validate targets and evaluate gene function.

 

Last August, Compugen struck a major platform licensing and DNA chip design deal with Novartis as part of the pharmaceutical giant's efforts to establish a comprehensive human transcriptome database.

 

For further information, see the press release.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.